PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP MEMORANDUM
FROM: Amy Whitfield and Sean Morrissey, Calderwood & Harkness LLP
TO: Declan Harrington, General Counsel & Company Secretary, Solstice Biomedical Devices Ltd. Siobhán Mulcahy, Head of Global Compliance, Solstice Biomedical Devices Ltd.
REVIEWED AND APPROVED BY: Joel Strauss, Partner, Healthcare & Life Sciences, Calderwood & Harkness LLP
DATE: June 14, 2024
RE: Federal Anti-Kickback Statute and False Claims Act Analysis — Solstice Biomedical Inc. US Commercial Operations
MATTER NO.: 1037-00003
This memorandum is a privileged and confidential attorney-client communication and attorney work product prepared at the direction of counsel. It is intended solely for the use of the addressees identified above and such other persons as they may designate in writing. This memorandum should not be disclosed to any third party without the prior written consent of Calderwood & Harkness LLP. Disclosure to any third party may result in waiver of the attorney-client privilege and work product protection.
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to provide a comprehensive analysis of all planned United States commercial arrangements of Solstice Biomedical Inc. ("Solstice US" or the "Company"), a Delaware corporation and wholly owned subsidiary of Solstice Biomedical Devices Ltd. ("Solstice Parent"), under the federal Anti-Kickback Statute ("AKS"), 42 U.S.C. § 1320a-7b(b), and the federal False Claims Act ("FCA"), 31 U.S.C. §§ 3729–3733. This analysis is being provided in advance of the planned October 1, 2024 US commercial launch of the Pulsar™ CRM System.
Product Context. The Pulsar™ CRM System is a subcutaneous implantable cardiac monitor with an integrated cloud-based remote telemetry platform. The device received FDA 510(k) clearance on February 9, 2024 (510(k) No. K232847). The Pulsar™ CRM System is classified as a Class II medical device under Product Code MHX. The predicate device for the 510(k) submission was the CardioStar™ SC-200 by Vantage Medical Technologies Inc. (510(k) No. K201156). The Pulsar™ CRM System is designed for continuous cardiac rhythm monitoring in patients with suspected or diagnosed cardiac arrhythmias, with data transmitted via the cloud-based telemetry platform to treating physicians for real-time clinical analysis.
US Pricing and Revenue Projections. The US list price for the implantable monitor unit is $4,950 per unit, and the list price for the remote telemetry transmitter unit is $1,200 per unit. Based on current internal projections provided by Solstice's US commercial leadership, projected US Year-1 revenue is $26 million for the fiscal year ending December 31, 2025. These revenue projections form the baseline for the financial assumptions underlying the commercial arrangements analyzed in this memorandum.
Arrangements Analyzed. This memorandum analyzes the following five categories of planned US commercial arrangements:
1. The exclusive distribution agreement with Ascendant Distribution Solutions LLC ("ADS") (Agreement No. SBD-ADS-2024-0315, dated March 15, 2024);
2. Physician consulting agreements under the Key Opinion Leader ("KOL") program;
3. Physician speaker programs;
4. Territory manager and sales leadership compensation structures; and
5. Meal and hospitality practices associated with commercial activities.
Overall Conclusion. Based on our review, it is our assessment that, with the implementation of the recommended structural safeguards and documented compliance controls detailed throughout this memorandum, each of the analyzed arrangements can be structured to fit within recognized AKS statutory safe harbors or, where safe harbor protection is not fully available, to substantially mitigate enforcement risk under both the AKS and the FCA. However, several of the arrangements present meaningful compliance risk that requires affirmative remediation before the October 1, 2024 launch date. The highest-priority items include obtaining an independent fair market value opinion for the ADS distribution commission structure, strengthening compliance provisions in the ADS Distribution Agreement, implementing compliance metrics and clawback provisions in the sales compensation plan, and establishing robust controls over the speaker program. Specific risk areas and detailed remediation steps are identified throughout each section of this memorandum.
This analysis should be read in conjunction with the companion memoranda on Sunshine Act compliance, FDA promotional compliance, state marketing compliance, and the comprehensive compliance framework report, each of which is being provided separately.
II. Legal Framework
This Section provides an overview of the principal federal statutes and regulatory guidance applicable to Solstice's planned US commercial arrangements. The legal framework set forth here informs the arrangement-specific analyses in Sections III through VIII.
A. The Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b))
The federal Anti-Kickback Statute is codified at 42 U.S.C. § 1320a-7b(b). It is a criminal statute that prohibits any person from knowingly and willfully offering, paying, soliciting, or receiving any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward any person for: (1) referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a federal healthcare program; or (2) purchasing, leasing, ordering, or arranging for or recommending the purchasing, leasing, or ordering of any good, facility, service, or item for which payment may be made in whole or in part under a federal healthcare program.
The AKS is an intent-based statute. The statute requires that the remuneration be offered, paid, solicited, or received "knowingly and willfully." However, the scienter requirement was modified significantly by Section 6402(f) of the Patient Protection and Affordable Care Act (the "ACA"). Under the ACA amendment, a person need not have actual knowledge of the AKS or specific intent to violate the statute in order to commit a violation. This broadened scienter standard has lowered the bar for federal prosecutors and has been relied upon in numerous post-ACA enforcement actions.
Courts have adopted a broad interpretation of the AKS's reach under what is commonly referred to as the "one purpose" test. Under this standard, if even one purpose of the remuneration is to induce or reward referrals of items or services reimbursable under federal healthcare programs, the AKS is violated—even if there are other legitimate, non-referral-related purposes for the payment. See, e.g., United States v. Greber, 760 F.2d 68 (3d Cir. 1985); United States v. Borrasi, 639 F.3d 774 (7th Cir. 2011). This one-purpose standard significantly expands the scope of conduct that may fall within the statute's prohibition, because in many commercial relationships in the healthcare industry, remuneration may serve multiple purposes simultaneously.
The term "remuneration" is interpreted broadly by the courts and the Office of Inspector General of the U.S. Department of Health and Human Services ("OIG"). It encompasses any transfer of value, whether in the form of cash payments, commissions, consulting fees, speaker honoraria, meals, travel expenses, gifts, in-kind services, or any other economic benefit. The breadth of this definition means that virtually any financial arrangement between a medical device manufacturer and a person or entity in a position to refer, recommend, or arrange for the purchase of the manufacturer's products may implicate the AKS.
Penalties. Violations of the AKS carry severe consequences. A violation constitutes a criminal felony, punishable by up to five (5) years of imprisonment and a fine of up to $100,000 per violation. In addition, the OIG may impose civil monetary penalties of up to $100,000 per violation, plus treble damages (three times the amount of remuneration involved). Perhaps most consequentially for a commercial enterprise, a conviction or finding of an AKS violation results in mandatory exclusion from participation in all federal healthcare programs, including Medicare and Medicaid. For a medical device company, exclusion effectively eliminates the ability to sell products to the vast majority of the US healthcare market.
Application to Solstice. The Pulsar™ CRM System is reimbursable under Medicare and Medicaid. The implantation procedure and associated cardiac rhythm monitoring services are covered under existing Medicare payment codes for cardiac rhythm monitoring (including, without limitation, relevant CPT codes for subcutaneous cardiac rhythm device implantation and remote cardiac telemetry monitoring). Accordingly, all arrangements involving remuneration to physicians, distributors, or any other persons or entities in a position to refer, recommend, arrange for, or influence the purchase or use of the Pulsar™ CRM System are subject to AKS scrutiny. This includes the distribution commission paid to ADS, compensation paid to physician consultants and speakers, variable compensation paid to sales personnel, and meals and hospitality provided to healthcare professionals.
B. Statutory Safe Harbors (42 C.F.R. § 1001.952)
Congress recognized that the AKS, if applied literally to every payment arrangement in healthcare, could impede legitimate commercial activity and beneficial arrangements that do not pose a risk of fraud or abuse. Accordingly, Congress directed the OIG to promulgate regulatory safe harbors that describe specific payment practices that, if fully satisfied, will not be treated as violations of the AKS and will immunize the parties from criminal prosecution and civil enforcement under the statute. These safe harbors are codified at 42 C.F.R. § 1001.952.
It is important to emphasize that compliance with a safe harbor is a complete defense to AKS liability for the specific arrangement at issue, but the safe harbors are narrowly drawn, and strict compliance with every element is required. An arrangement that fails to satisfy one or more elements of a safe harbor does not, by that fact alone, violate the AKS, but it loses the absolute protection that the safe harbor affords and becomes subject to a totality-of-the-circumstances analysis by enforcement authorities. The following safe harbors are most relevant to Solstice's planned US commercial arrangements:
Personal Services and Management Contracts Safe Harbor (42 C.F.R. § 1001.952(d)). This safe harbor is directly applicable to the physician consulting agreements (KOL program) and the physician speaker program agreements. It is also potentially applicable to certain elements of the ADS Distribution Agreement. The safe harbor protects payments made by a principal to an agent as compensation for the agent's services, provided the following conditions are met:
(i) The arrangement is set out in a written agreement signed by the parties;
(ii) The agreement specifies the services to be provided by the agent;
(iii) If the agreement is intended to cover on a periodic, sporadic, or part-time basis, the agreement specifies exactly the schedule of such intervals, their precise length, and the exact charge for such intervals;
(iv) The term of the agreement is for not less than one year;
(v) The aggregate compensation paid to the agent over the term of the agreement is set in advance, is consistent with fair market value in arm's-length transactions, and is not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties for which payment may be made in whole or in part under a federal healthcare program; and
(vi) The services performed under the agreement do not involve the counseling or promotion of a business arrangement or other activity that violates any state or federal law.
Each of these elements is analyzed in detail in the arrangement-specific sections of this memorandum.
Employee Safe Harbor (42 C.F.R. § 1001.952(i)). This safe harbor protects any amount paid by an employer to an employee (who has a bona fide employment relationship with the employer) for employment in the provision of covered items or services. The employee safe harbor is applicable to the compensation paid to Solstice US's territory managers, regional directors, area vice presidents, and the VP of US Commercial Operations, all of whom are W-2 employees of Solstice Biomedical Inc. This safe harbor is broadly protective and does not impose the same fair market value ("FMV") or "set in advance" constraints that apply under the personal services safe harbor. Commission-based and incentive-based compensation structures for bona fide employees are generally protected under this safe harbor.
discount Safe Harbor (42 C.F.R. § 1001.952(h)). This safe harbor is potentially applicable to pricing arrangements under the ADS Distribution Agreement to the extent that discounts or reductions in price are offered to ADS or through ADS to healthcare provider customers. The discount safe harbor requires that discounts be properly disclosed and accurately reported. Specifically, the discount must be: (i) earned based on a buyer's purchases; (ii) properly disclosed by the seller to the buyer at the time of sale or, in the case of a rebate, at the time the rebate is paid; and (iii) the buyer must properly report the discount or reduction in price for purposes of federal healthcare program cost reporting.
Consequences of Not Fitting Within a Safe Harbor. An arrangement that does not squarely satisfy all elements of an applicable safe harbor is not, for that reason alone, illegal under the AKS. Rather, such an arrangement is analyzed under the totality of the circumstances, taking into account factors such as the purpose and structure of the arrangement, the nature and extent of the remuneration, the relationship between the remuneration and referrals, the existence of safeguards against abuse, and other indicia of the parties' intent. However, the loss of safe harbor protection means that the arrangement carries residual enforcement risk and may be subject to OIG scrutiny, DOJ investigation, or qui tam litigation.
C. The Federal False Claims Act (31 U.S.C. §§ 3729–3733)
The federal False Claims Act imposes civil liability on any person who: (1) knowingly presents, or causes to be presented, a false or fraudulent claim for payment or approval to the federal government; (2) knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim; or (3) conspires to commit any of the foregoing violations. The FCA's scienter requirement is met if the person acts with actual knowledge, deliberate ignorance, or reckless disregard of the truth or falsity of the information. No specific intent to defraud is required.
Implied Certification Theory. In Universal Health Services, Inc. v. United States ex rel. Escobar, 579 U.S. 176 (2016), the Supreme Court held that the implied certification theory can, in appropriate circumstances, provide a basis for FCA liability. Under this theory, a claim for payment can be "false" if the claimant makes specific representations about the goods or services provided but fails to disclose the claimant's noncompliance with a statutory, regulatory, or contractual requirement, and that noncompliance renders those representations misleading with respect to the goods or services provided. Importantly, the Escobar Court held that the noncompliance must be "material" to the government's payment decision. Although the Court emphasized that materiality is a demanding standard, it also acknowledged that violations of conditions of participation in federal healthcare programs may be material in many circumstances.
AKS-FCA Nexus. Section 6402(f) of the ACA expressly provides that a claim that includes items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA. This statutory linkage is critically important for Solstice, because it means that any underlying AKS violation in connection with the promotion or sale of the Pulsar™ CRM System can transform every related Medicare or Medicaid claim into a false claim under the FCA. The implications for aggregate liability exposure are profound, as discussed in Section VIII below.
Penalties. The FCA imposes treble damages (three times the amount of the government's actual damages) plus per-claim civil penalties. As adjusted for inflation for penalties assessed after January 29, 2024, the per-claim penalty range is $13,946 to $27,894 per false claim. Given the volume of federal healthcare program claims anticipated in connection with Pulsar™ CRM System implantations and monitoring services, even a narrow category of tainted claims could generate aggregate FCA exposure in the tens or hundreds of millions of dollars.
Qui Tam Provisions. The FCA contains robust qui tam provisions that permit private individuals (known as "relators" or, colloquially, "whistleblowers") to file suit on behalf of the federal government. If the government intervenes in a qui tam action and recovers, the relator is entitled to a share of the recovery, typically between 15% and 25%. If the government declines to intervene and the relator proceeds independently and obtains a recovery, the relator's share increases to between 25% and 30%. These financial incentives have made qui tam litigation a powerful enforcement mechanism. Potential relators relevant to Solstice include current and former sales force employees (particularly territory managers who may observe compliance failures in the field), distributor personnel, sub-distributor personnel, physician consultants, and other persons with knowledge of Solstice's commercial practices.
Relevance to Solstice. Every claim for Medicare or Medicaid reimbursement for the Pulsar™ CRM System submitted by hospitals, physicians, or other healthcare providers could become a false claim under the FCA if that claim is tainted by an underlying AKS violation related to Solstice's commercial arrangements. With $26 million in projected Year-1 US revenue and the corresponding volume of federal healthcare program claims, the Company's FCA exposure is substantial and represents a material financial and operational risk. Mitigation of FCA exposure is therefore a central objective of the compliance program recommendations set forth in this memorandum.
D. OIG Compliance Guidance
The OIG has issued several guidance documents that, while not having the force of law, are highly influential in establishing compliance expectations and are relied upon by courts, enforcement authorities, and juries in evaluating the adequacy of a company's compliance program.
OIG General Compliance Program Guidance (November 2023). In November 2023, the OIG issued updated general compliance program guidance applicable to all participants in federal healthcare programs. This guidance supersedes certain earlier guidance documents and establishes an updated framework for effective compliance programs. The November 2023 guidance reaffirms and expands upon the seven elements of an effective compliance program, which the OIG considers foundational for any entity participating in federal healthcare programs: (1) written standards of conduct, policies, and procedures; (2) designation of a compliance officer and compliance committee; (3) effective training and education; (4) effective lines of communication, including a mechanism for anonymous reporting; (5) internal monitoring and auditing; (6) enforcement of standards through well-publicized disciplinary guidelines; and (7) prompt response to detected offenses and implementation of corrective action. These seven elements are discussed further in Section IX.
OIG Compliance Program Guidance for Pharmaceutical Manufacturers (April 2003). Although styled as guidance for pharmaceutical manufacturers, this document has been widely adapted and applied by the OIG, DOJ, and the medical device industry to medical device companies. The April 2003 guidance identifies specific risk areas that are directly relevant to Solstice's planned commercial arrangements, including sales force compensation, consulting arrangements with healthcare professionals, speaker programs, educational grants, and distribution arrangements. The guidance emphasizes the importance of fair market value compensation, legitimate business need for services, independence of compensation from referral volume, and robust documentation of services rendered.
AdvaMed Code of Ethics on Interactions with Healthcare Professionals (2020 Revision). The Advanced Medical Technology Association ("AdvaMed") promulgates a voluntary industry code of ethics governing interactions between medical device companies and healthcare professionals. The 2020 Revision of the AdvaMed Code establishes standards for consulting arrangements, speaker programs, meals and hospitality, educational events, grants, and other interactions. While the AdvaMed Code is not law and does not constitute a safe harbor, the OIG has referenced the AdvaMed Code in its guidance as a relevant benchmark, and adherence to the Code is widely regarded as a best practice that supports a company's compliance posture. Solstice has adopted the AdvaMed Code of Ethics (2020 Revision) as the baseline for all US interactions with healthcare professionals, and the Code's standards are referenced throughout this memorandum.
III. Analysis of the ADS Distribution Agreement
A. Agreement Structure
Solstice Biomedical Devices Ltd. has entered into an exclusive distribution agreement with Ascendant Distribution Solutions LLC ("ADS") for the distribution of the Pulsar™ CRM System throughout the United States. The key terms of the agreement, referenced herein as Agreement No. SBD-ADS-2024-0315, dated March 15, 2024, are as follows:
Parties. The contracting parties are Solstice Biomedical Devices Ltd., an Irish limited company with its registered office in Dublin, Ireland (the "Supplier"), and Ascendant Distribution Solutions LLC, a Delaware limited liability company with its principal office in Pittsburgh, Pennsylvania (the "Distributor").
Term. The initial term of the agreement is five (5) years, commencing March 15, 2024 and expiring March 14, 2029. The agreement provides for two (2) successive two-year renewal options, exercisable by mutual written consent of the parties, which could extend the agreement through March 14, 2033.
Scope. ADS has been granted exclusive distribution rights for the Pulsar™ CRM System (including the implantable cardiac monitor unit and the remote telemetry transmitter unit) across all fifty (50) US states and US territories, including Puerto Rico, Guam, the US Virgin Islands, American Samoa, and the Northern Mariana Islands. Exclusivity is subject to Solstice's retained right to sell directly to federal government accounts (VA, DoD) and to designated group purchasing organizations, as set forth in Schedule 3 to the agreement.
Commission. ADS is entitled to a commission of eighteen percent (18%) of net US sales, defined as the aggregate invoiced amount for Pulsar™ CRM System products sold through or by ADS in the US territory, net of returns, allowances, chargebacks, and applicable taxes. Based on the Company's projected Year-1 US revenue of $26 million, the estimated Year-1 commission payable to ADS is approximately $4.68 million.
Sub-Distributors. The agreement permits ADS to engage up to five (5) authorized sub-distributors to assist in the distribution of the Pulsar™ CRM System within the US territory. Each sub-distributor appointment requires Solstice's prior written approval and the sub-distributor's execution of a Compliance Certification in the form attached as Exhibit D to the agreement. ADS retains primary responsibility for the performance and compliance of its sub-distributors.
Audit Rights. Section 12 of the agreement grants Solstice the right to audit ADS's compliance records. Under the current terms, Solstice may conduct up to two (2) compliance audits per calendar year, with thirty (30) days' prior written notice to ADS. ADS is obligated to cooperate with such audits and to make available all records reasonably requested by Solstice in connection with the audit.
ADS Profile. ADS is a substantial and sophisticated distribution enterprise. For its fiscal year ended December 31, 2023, ADS reported annual revenue of approximately $214 million. ADS maintains an existing compliance infrastructure, including a dedicated compliance function led by Dawn Hitchens, Vice President of Compliance & Legal. ADS is represented in this transaction by the law firm of Hadley, Ostrander & Paige LLP, based in Cleveland, Ohio, with partner Gregory Paige serving as lead outside counsel.
B. AKS Analysis — Commission Structure
The 18% commission on net US sales payable to ADS constitutes "remuneration" within the meaning of the AKS. ADS, through its sales and distribution personnel, is in a position to recommend, arrange for, or influence the purchase of the Pulsar™ CRM System by hospitals, physician practices, and other healthcare provider customers. ADS personnel interact directly with healthcare providers during the sales process, including presenting product information, negotiating pricing and terms, processing orders, and managing customer relationships. These activities place ADS squarely within the class of persons whose receipt of remuneration from a device manufacturer triggers AKS scrutiny.
The primary safe harbor applicable to the ADS commission arrangement is the Personal Services and Management Contracts Safe Harbor, 42 C.F.R. § 1001.952(d). We have analyzed the ADS Distribution Agreement against each element of this safe harbor:
Written Agreement Signed by the Parties. The ADS Distribution Agreement is in writing and has been duly executed by authorized representatives of both parties. This element is satisfied.
Specifies Services to Be Provided. Article 3 of the agreement sets forth the distribution services to be provided by ADS, including warehousing, logistics, order processing, customer support, product training coordination, and certain marketing support functions. While the description of services is generally adequate, we recommend supplementing Exhibit B (Services Description) with additional specificity regarding ADS's obligations with respect to compliance-related activities, including compliance training for ADS personnel, compliance monitoring, and adverse event reporting.
Term of at Least One Year. The agreement has an initial term of five (5) years, which comfortably exceeds the one-year minimum. This element is satisfied.
Aggregate Compensation Set in Advance, Consistent with Fair Market Value, and Not Determined in a Manner That Takes into Account the Volume or Value of Referrals. This element presents the most significant analytical challenge. The 18% commission is expressed as a percentage of net US sales, which means that aggregate compensation payable to ADS over the term of the agreement is not a fixed amount but varies directly with the volume of product sales. This inherent variability creates tension with the "set in advance" requirement as traditionally interpreted by the OIG.
The OIG has historically expressed concern about percentage-based compensation arrangements for non-employee agents and distributors, because such arrangements tie the agent's compensation directly to the volume of business generated. In Advisory Opinion No. 99-13 and subsequent opinions, the OIG has noted that percentage-based compensation may not satisfy the "set in advance" element of the personal services safe harbor in all circumstances. However, the OIG has also acknowledged that the safe harbor does not categorically exclude percentage-based fees and that such arrangements may be permissible where appropriate safeguards are in place.
The critical question is whether the 18% commission rate reflects fair market value for the distribution services being provided. To assess this question, the commission rate should be benchmarked against industry norms for exclusive medical device distribution agreements in the cardiac rhythm management and related cardiovascular device categories. Based on our experience representing medical device companies in analogous distribution arrangements, exclusive distribution commissions in the cardiovascular device space typically range from 12% to 22% of net sales, depending on the scope of services provided, the exclusivity of the territory, the maturity of the product, and the distributor's infrastructure and capabilities. The 18% rate falls within this range but is above the midpoint.
We strongly recommend that Solstice obtain an independent fair market value opinion from a qualified healthcare valuation firm (such as ECRI Institute, Harborview Management Consulting, or a comparable firm with recognized expertise in medical device distribution valuation) to support the 18% commission rate. The FMV opinion should analyze the specific services being provided by ADS, the scope of the exclusive territory, the value of ADS's existing distribution infrastructure and customer relationships, and comparable distribution arrangements in the CRM and broader cardiovascular device market.
Several mitigating factors support the commercial reasonableness and legitimacy of the ADS commission structure:
(i) The 18% commission rate was negotiated at arm's length between Solstice and ADS, two unrelated commercial entities represented by independent legal counsel;
(ii) ADS brings substantial legitimate distribution infrastructure to the relationship, including nationwide warehousing and logistics capabilities, an established customer base of hospital and healthcare provider accounts, dedicated customer service operations, and field-level sales support;
(iii) ADS's annual revenue of $214 million demonstrates that it is an established, financially substantial commercial entity, not a shell company or a vehicle primarily designed for referral generation; and
(iv) The distribution services provided by ADS are genuine, documented, and necessary for Solstice's US commercial launch, given that Solstice US does not currently maintain its own distribution infrastructure in the United States.
Remaining Risk. Notwithstanding these mitigating factors, we must note that the percentage-based commission structure does not squarely satisfy the "set in advance" requirement as most conservatively interpreted, because aggregate compensation varies directly with volume. This structural feature means that the arrangement does not enjoy the full, unqualified protection of the personal services safe harbor. The arrangement is therefore subject to a totality-of-the-circumstances analysis, under which the mitigating factors described above, combined with the additional compliance safeguards recommended in Section III.E below, would be weighed against the volume-linked nature of the compensation. We assess the overall AKS risk for this arrangement as Medium-High, principally due to the magnitude of the commission payments ($4.68 million projected Year-1) and the absence of a fixed aggregate compensation amount.
C. Sub-Distributor Compliance
The ADS Distribution Agreement permits ADS to engage up to five (5) authorized sub-distributors to assist in the distribution of the Pulsar™ CRM System. While the use of sub-distributors is common in the medical device distribution industry and can serve legitimate commercial purposes, sub-distribution arrangements introduce additional layers of compliance risk.
Sub-distributors are one step further removed from Solstice's direct compliance oversight. Each sub-distributor relationship represents an additional point at which remuneration flows to persons or entities that may be in a position to influence healthcare provider purchasing decisions. Under established AKS jurisprudence, liability can extend to arrangements that indirectly induce referrals, even where the inducement flows through intermediaries. The use of sub-distributors thus expands the chain of potential AKS liability.
The current agreement requires each sub-distributor to execute a Compliance Certification (Exhibit D), which is an important safeguard. However, the Compliance Certification as currently drafted is limited in scope and does not incorporate the full range of compliance protections that we recommend. Specifically, we note the following concerns and recommendations:
(i) Flow-Down of Compliance Obligations. The agreement should require ADS to flow down all material compliance obligations—including AKS and FCA compliance requirements, training obligations, and record-keeping requirements—to each sub-distributor through the sub-distribution agreement. The current Compliance Certification does not expressly require this flow-down.
(ii) Compliance Training. Each sub-distributor and its personnel involved in the marketing, sale, or distribution of the Pulsar™ CRM System should be required to complete AKS/FCA compliance training substantially equivalent to the training required of ADS's own personnel. This training should be completed before the sub-distributor commences distribution activities and should be renewed annually.
(iii) Termination Rights. Solstice should retain the express right to require ADS to terminate any sub-distributor appointment if Solstice reasonably determines that the sub-distributor has committed a compliance violation. The current agreement provides for Solstice's prior written approval of sub-distributor appointments but does not expressly address Solstice's right to compel termination on compliance grounds.
(iv) Fair Market Value Compensation. The compensation paid by ADS to each sub-distributor should be documented as consistent with fair market value for the services provided. ADS should be required to provide Solstice with documentation of sub-distributor compensation arrangements, and Solstice should have the right to review and approve such arrangements.
D. Audit Rights
The audit rights provision in Section 12 of the ADS Distribution Agreement currently permits Solstice to conduct up to two (2) compliance audits per calendar year, with thirty (30) days' prior written notice to ADS. While this provision represents a meaningful compliance safeguard, we believe it should be strengthened in several respects to ensure adequate compliance oversight and to enhance Solstice's defense posture in the event of a government investigation or qui tam action.
We recommend the following amendments to the audit rights provision:
(i) Shortened Notice Period for Suspected Violations. In addition to the standard 30-day notice period for routine audits, Solstice should have the right to conduct audits on shortened notice (e.g., ten (10) business days) in cases where Solstice has a reasonable basis to suspect a compliance violation by ADS or any sub-distributor. This shortened notice period is necessary to preserve the integrity of compliance records and to enable prompt investigation of suspected violations.
(ii) Extension to Sub-Distributor Records. The audit rights should expressly extend to the compliance records of ADS's authorized sub-distributors. ADS should be required to include corresponding audit rights provisions in its sub-distribution agreements and to facilitate Solstice's access to sub-distributor records upon request.
(iii) Record Retention Requirements. ADS should be required to maintain all compliance-related records—including records of sales activities, commission calculations, sub-distributor compensation, compliance training, and customer interactions—for a minimum of six (6) years from the date of creation. This retention period aligns with the FCA statute of limitations and with the document retention requirements applicable to Medicare cost report records.
(iv) Annual Compliance Certifications. ADS should be required to deliver to Solstice an annual compliance certification, signed by a senior officer of ADS (at a minimum, the Chief Executive Officer or the VP of Compliance & Legal), attesting to ADS's compliance with the AKS, FCA, and applicable provisions of the distribution agreement during the preceding calendar year. The compliance certification should include a representation that ADS has no knowledge of any compliance violations by ADS or its sub-distributors during the certification period.
E. Recommendations for ADS Distribution Agreement
Based on the foregoing analysis, we recommend the following actions with respect to the ADS Distribution Agreement:
1. Obtain Independent FMV Opinion. Solstice should retain a qualified healthcare valuation firm to prepare an independent fair market value opinion supporting the 18% commission rate. The FMV opinion should be completed before the October 1, 2024 commercial launch and should be retained in Solstice's compliance files.
2. Amend Compliance and Audit Provisions. Sections 7 (Compliance) and 12 (Audit Rights) of the agreement should be amended to incorporate the enhanced compliance provisions described in Sections III.C and III.D above. Proposed redline amendments to these sections will be provided under separate cover in the distributor compliance review memorandum.
3. Include Express AKS and FCA Compliance Representations and Warranties. The agreement should be amended to include express representations and warranties from ADS regarding compliance with the AKS, FCA, and applicable state anti-kickback and false claims statutes. These representations should survive termination of the agreement for a period of not less than six (6) years.
4. Add Sunshine Act Data-Collection and Reporting Obligations. ADS should be contractually required to collect and provide to Solstice all data necessary for Solstice to comply with its reporting obligations under the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h) and the implementing Open Payments regulations. This includes data on meals, hospitality, consulting fees, travel, and any other transfers of value to covered recipients made by ADS or its sub-distributors in connection with the distribution of the Pulsar™ CRM System.
5. Include Compliance Training Requirements. The agreement should require all ADS personnel involved in marketing, selling, or distributing the Pulsar™ CRM System to complete AKS/FCA compliance training developed or approved by Solstice, with initial training to be completed before the commencement of distribution activities and annual refresher training thereafter.
6. Add Termination-for-Cause Provisions. The agreement should include a termination-for-cause provision that expressly permits Solstice to terminate the agreement (or require the termination of any sub-distributor appointment) in the event of a material AKS or FCA violation by ADS or any sub-distributor. The termination-for-cause provision should be exercisable by Solstice in its reasonable discretion and should not require prior notice or opportunity to cure for violations involving fraud, bribery, or knowing and willful noncompliance with the AKS or FCA.
IV. Analysis of Physician Consulting Agreements (KOL Program)
A. Program Structure
Solstice plans to engage up to thirty-five (35) physician consultants as Key Opinion Leaders ("KOLs") during the first year of the US commercial launch. The KOL program is designed to provide Solstice with clinical advisory input, product development feedback, market research insights, and support in the development of clinical training materials. The physicians selected for the KOL program are expected to be recognized experts in cardiac electrophysiology, cardiac rhythm management, and related cardiovascular subspecialties.
Compensation for KOL consulting services will be based on an hourly rate ranging from $350 to $500 per hour, tiered according to the consultant's medical specialty, academic rank, and level of clinical experience. This tiered approach recognizes that physicians with greater expertise, academic distinction, and clinical authority command higher consulting rates in the marketplace.
Solstice has established an annual per-consultant compensation cap of $12,000, which limits the total consulting fees payable to any individual physician in a single calendar year. Based on the hourly rate range, this cap effectively limits each consultant to between 24 hours (at $500/hour) and approximately 34 hours (at $350/hour) of consulting services per year.
The services to be performed by KOL consultants are expected to include, without limitation: (i) providing clinical advisory input on the design, functionality, and clinical application of the Pulsar™ CRM System and future product iterations; (ii) participating in product development feedback sessions and providing written evaluations of prototype devices and software features; (iii) participating in market research activities, including focus groups and structured interviews regarding unmet clinical needs in cardiac rhythm monitoring; and (iv) contributing to the development of clinical training curricula and educational materials for use by Solstice's medical affairs team and clinical specialists.
B. AKS Analysis — Personal Services and Management Contracts Safe Harbor
The KOL consulting program must be structured to satisfy the requirements of the Personal Services and Management Contracts Safe Harbor, 42 C.F.R. § 1001.952(d). The physician consultants are healthcare professionals who are in a position to refer, recommend, or arrange for the use of the Pulsar™ CRM System. The consulting fees constitute remuneration under the AKS. Accordingly, safe harbor compliance is critical to mitigating AKS risk. Below, we analyze each element of the safe harbor as applied to the KOL program:
(i) Written Agreement Signed by the Parties. Each KOL engagement will be documented through a written consulting agreement (the "Template Consulting Agreement"), which will be executed by the physician consultant and by an authorized representative of Solstice Biomedical Inc. The Template Consulting Agreement is currently being prepared by this firm and will be delivered under separate cover. This element will be satisfied.
(ii) Agreement Specifies the Services to Be Provided. The Template Consulting Agreement will include an Exhibit A (Scope of Services) that details the specific services to be provided by each consultant. It is essential that Exhibit A be tailored for each individual engagement and include a detailed description of the services to be rendered, the expected deliverables, the anticipated time commitment, and the specific business need that the engagement is designed to address. Blanket or vague descriptions of services (e.g., "provide general consulting services as requested") are insufficient to satisfy this element and would undermine the compliance posture of the program. Each Exhibit A should be drafted with specificity and reviewed by the Compliance Committee before execution.
(iii) Term of at Least One Year (or Precisely Defined Intervals). We recommend that each KOL consulting agreement have an initial term of one (1) year, with the possibility of renewal upon mutual written agreement of the parties. Annual agreements provide a natural checkpoint for reassessing the business need for the engagement and the consultant's performance. This structure satisfies the one-year minimum term requirement.
(iv) Aggregate Compensation Set in Advance. The KOL program establishes hourly rates of $350 to $500 per hour, with an annual per-consultant cap of $12,000. These rates and the annual cap will be specified in the Template Consulting Agreement. The "set in advance" requirement is satisfied when the methodology for calculating compensation (i.e., the hourly rate) and the maximum aggregate compensation (i.e., the annual cap) are determined before the services are performed and are documented in the written agreement. This element is satisfied, provided that the rates and cap are clearly stated in each agreement and are not modified after execution based on referral or ordering activity.
(v) Compensation Consistent with Fair Market Value. The hourly rate range of $350 to $500 must be consistent with fair market value for physician consulting services in the cardiac rhythm management space. Fair market value is generally defined as the compensation that would be agreed upon by a willing buyer and a willing seller, neither being under compulsion, and both having reasonable knowledge of the relevant facts. We recommend that Solstice obtain an independent FMV survey or benchmarking analysis of physician consultant compensation in the CRM and cardiac electrophysiology space to validate the proposed rate range. Based on our experience with comparable arrangements in the medical device industry, hourly rates of $350 to $500 for physician consultants in cardiac specialties are within the range of prevailing FMV, but formal validation is prudent and would significantly strengthen the Company's compliance position.
The tiering of rates by specialty and academic rank is an appropriate and defensible methodology. Physicians holding full professorships at academic medical centers, physicians with extensive publications in peer-reviewed journals, and physicians with national or international recognition in the field of cardiac rhythm management appropriately command higher rates than early-career physicians or physicians in general cardiology practice.
(vi) Compensation Does Not Take into Account the Volume or Value of Referrals. This is the most critical element for compliance purposes. Consulting fees must be entirely decoupled from the consultant's ordering, prescribing, recommending, or referral patterns for the Pulsar™ CRM System. The hourly rate and annual cap must be determined solely on the basis of the consultant's qualifications, the nature of the services to be performed, and fair market value—not on the basis of the consultant's actual or anticipated referral volume. Solstice must not select consultants based on their referral potential, increase compensation based on referral activity, or terminate consultants for insufficient referral volume. Any evidence that consulting fees are functioning as rewards for referrals, or as inducements for future referrals, would be devastating to the Company's compliance position.
C. Risk Areas
Notwithstanding the availability of the personal services safe harbor, several risk areas require careful attention and ongoing monitoring:
Selection Bias. The OIG has identified the selection of physician consultants based on their referral potential, rather than their legitimate expertise and the Company's genuine business need for their services, as a primary compliance concern. The risk is that the KOL program functions, in substance, as a mechanism for cultivating referral relationships with high-prescribing physicians under the guise of consulting. To mitigate this risk, the selection of each KOL consultant must be based on documented, legitimate criteria—including the physician's clinical expertise, research experience, academic standing, and publication record—and must be supported by a documented assessment of the specific business need that the engagement is designed to address. The selection process should be managed by the Medical Affairs function (under Dr. Nadia Farouk) rather than by the commercial organization, to ensure appropriate separation between consulting engagements and sales activities.
Volume of Consultants. Engaging thirty-five (35) KOL consultants in the first year of a US commercial launch is at the higher end of what would be expected for a product of this type and at this stage of commercialization. While a new product launch may generate legitimate needs for extensive clinical input and market research, the volume of consultant engagements must be supported by documented legitimate business needs for each individual engagement. Solstice should prepare and maintain a written KOL program justification document that identifies the specific business objectives of the program, the categories of expertise needed, and the rationale for the overall number of consultants to be engaged. This document should be reviewed and approved by the Compliance Committee before the KOL program commences.
"Parking" Arrangements. A "parking" arrangement is one in which consulting fees are paid to a physician ostensibly for consulting services but in reality function as payments for loyalty, product switching, or general goodwill, without genuine services being rendered in exchange. The risk of a parking arrangement increases when consulting engagements lack specificity, when deliverables are vague or nominal, or when the Company fails to maintain contemporaneous documentation of services actually performed. Solstice must maintain detailed contemporaneous records of all services provided by each KOL consultant, including hours worked, deliverables produced, meeting attendance, written feedback provided, and any other documentation of the consultant's contribution. These records are essential to demonstrating, in the event of an investigation, that the consulting fees represent payment for genuine services of value to the Company.
Overlap with Speaker Program. Some physicians may be engaged as both KOL consultants and speakers in the speaker program. This overlap creates cumulative compensation that may raise red flags with enforcement authorities. As discussed further in Section V below, aggregate compensation per physician across all programs should be tracked and subject to defined thresholds. We recommend that Solstice implement an annual aggregate compensation report for each physician receiving compensation under any Solstice program, including consulting fees, speaker honoraria, meals, travel reimbursement, and any other transfers of value. No physician should serve as both a KOL consultant and a speaker if the aggregate annual compensation from all Solstice programs would exceed $25,000, unless the Compliance Committee reviews and approves the exception based on a documented, compelling business justification.
D. Recommendations
Based on the foregoing analysis, we recommend the following actions with respect to the KOL consulting program:
1. Documented Legitimate Business Need Assessment. Before engaging each KOL consultant, Solstice should complete a written business need assessment that identifies the specific services to be provided, the business objective to be achieved, the qualifications that make the selected physician uniquely suited to provide the services, and the rationale for engaging this particular physician rather than an alternative candidate. This assessment should be prepared by the Medical Affairs function and reviewed by the Compliance Committee.
2. Written Records of Services Performed. Solstice should maintain contemporaneous written records of all services performed by each KOL consultant, including detailed time records, descriptions of work performed, copies of deliverables, meeting minutes, and any other documentation of the consultant's contribution. These records should be maintained for a minimum of six (6) years.
3. Annual Aggregate Compensation Report. Solstice should implement a centralized tracking system for all compensation and transfers of value to each physician across all programs—including consulting, speaking, meals, travel, and any other transfers of value. An annual aggregate compensation report should be generated for each physician and reviewed by the Compliance Committee.
4. Aggregate Compensation Cap. No physician should receive aggregate annual compensation from all Solstice programs exceeding $25,000, unless the Compliance Committee reviews and approves the exception in writing based on a documented, compelling business justification. This cap is designed to prevent the accumulation of financial relationships that could be perceived as inducements for referrals.
5. Annual FMV Benchmarking. Solstice should conduct an annual fair market value benchmarking review of KOL consulting hourly rates to confirm that the rate range of $350 to $500 per hour remains consistent with prevailing FMV. The benchmarking analysis should be documented and retained in the compliance files.
6. Template Consulting Agreement. The Template Consulting Agreement, to be delivered under separate cover, will include the following key provisions: (i) FMV compensation at the applicable hourly rate with the $12,000 annual cap; (ii) a written scope of services (Exhibit A) tailored to each engagement; (iii) compliance representations and warranties by the consultant; (iv) Sunshine Act disclosure acknowledgment; (v) termination-for-cause provisions tied to compliance violations; and (vi) provisions prohibiting the consultant from engaging in off-label promotion of the Pulsar™ CRM System.
V. Analysis of Speaker Programs
A. Program Structure
Solstice plans to conduct a total of one hundred eighty (180) speaker programs during the first year of the US commercial launch, consisting of one hundred twenty (120) live, in-person programs and sixty (60) virtual programs. Speaker programs are a common tool in the medical device industry for disseminating clinical and educational content about a product's cleared indications, clinical efficacy, and proper use to healthcare professionals.
Speaker honoraria are set at $1,500 per live, in-person presentation and $750 per virtual presentation. The annual per-speaker compensation cap is $18,000, which limits each speaker to a maximum of twelve (12) live programs (12 × $1,500 = $18,000), twenty-four (24) virtual programs (24 × $750 = $18,000), or some equivalent combination thereof in a single calendar year.
The estimated total Year-1 speaker program spend is $225,000, calculated as follows: (120 live programs × $1,500 per program = $180,000) + (60 virtual programs × $750 per program = $45,000) = $225,000. This estimate reflects honoraria payments only and does not include associated costs for venue rental, meals, audiovisual equipment, or travel, which are budgeted separately.
The per-person meal and hospitality cap for speaker program events is $150 per attendee per event, which is aligned with the AdvaMed Code of Ethics (2020 Revision) meal limit for healthcare professional events.
B. AKS Analysis — Personal Services and Management Contracts Safe Harbor
The speaker program is analyzed under the same Personal Services and Management Contracts Safe Harbor, 42 C.F.R. § 1001.952(d), that applies to the KOL consulting program. The speakers are physicians or other healthcare professionals who are in a position to refer, recommend, or influence the use of the Pulsar™ CRM System, and the speaker honoraria constitute remuneration under the AKS. The safe harbor analysis parallels the analysis set forth in Section IV.B, with the following observations specific to the speaker program:
Written Agreement. Each speaker will be engaged under a Template Speaker Program Agreement, to be prepared by this firm and delivered under separate cover. The agreement will set forth the terms and conditions of the speaker's engagement, including compensation, program format, and compliance obligations. This element will be satisfied.
Services Specified. The services to be specified in the speaker agreement consist of delivering presentations on the Pulsar™ CRM System using Solstice-approved slide decks. The scope of services should be clearly defined: the speaker is to present on the product's cleared indications, clinical evidence, implantation technique, remote monitoring capabilities, and other topics within the scope of the FDA-cleared labeling. The agreement should expressly prohibit the speaker from making off-label statements or presenting unapproved claims.
Term and Compensation Set in Advance. Annual speaker agreements are recommended, with the per-program honoraria ($1,500 for live; $750 for virtual) and the $18,000 annual cap stated in the agreement. This structure satisfies the "set in advance" requirement.
Fair Market Value. Honoraria of $1,500 per live presentation and $750 per virtual presentation should be benchmarked against prevailing FMV for medical device speaker programs in the CRM and cardiac electrophysiology space. Based on our experience, these rates appear within the range of industry norms for programs of this type, but formal FMV validation is recommended. The differential between live and virtual program honoraria is appropriate and reflects the additional time, travel, and preparation associated with in-person presentations.
No Volume or Value of Referrals. Speaker honoraria must be completely independent of the speaker's ordering, prescribing, or referral patterns for the Pulsar™ CRM System. Selection of speakers, invitation to present at specific programs, and compensation must be based solely on the speaker's qualifications, presentation skills, and the educational needs of the audience—not on the speaker's actual or anticipated use of the Pulsar™ CRM System.
C. Risk Areas
Speaker programs represent one of the highest-risk commercial arrangements in the medical device industry from an AKS compliance perspective. The OIG has repeatedly identified speaker programs as a primary area of concern, and the Department of Justice has brought numerous enforcement actions targeting medical device and pharmaceutical speaker programs that were found to lack genuine educational purpose or to function as vehicles for rewarding high-prescribing physicians.
The following specific risk areas require careful attention:
"Sham" Speaker Programs. The most significant risk is that speaker programs are structured or conducted in a manner that lacks genuine educational purpose and instead serves primarily to reward high-volume prescribers or to induce referrals. The OIG and DOJ have identified several indicators of sham speaker programs, including: (i) programs addressing topics for which there is no genuine educational need in the audience; (ii) programs with minimal or zero attendance (i.e., the speaker is paid but few or no attendees are present to receive the educational content); (iii) repeat presentations of the same content to the same audience; (iv) programs held at high-end restaurants, resorts, or entertainment venues where the meal or setting, rather than the educational content, is the primary attraction; and (v) payments to speakers who provide few or no actual presentations over the course of the agreement term. Any of these indicators, if present in Solstice's speaker programs, would significantly increase AKS enforcement risk and could provide the basis for a government investigation or qui tam action.
Venue and Hospitality Risk. The $150 per-attendee per-event meal and hospitality cap is aligned with the AdvaMed Code of Ethics (2020 Revision) and is an important safeguard. However, compliance with the per-person cap alone is not sufficient. Venue selection is independently significant. Programs held at resort locations, golf clubs, entertainment venues, or restaurants known primarily for their exclusive dining experience (rather than their suitability as a venue for professional educational programs) create an appearance of lavish entertainment that can undermine the educational purpose of the program, even if the per-person meal cost is within the cap. Venue selection should be documented, and each venue should be selected based on its suitability for the educational